Amarin’s Vascepa May Give Lovaza A Run For Its Money
21:18 EDT 26 Jul 2012 | Elsevier Business Intelligence
Label for Amarin’s EPA-only omega-3 fatty acid therapy notes that in patients with really high triglycerides, triglycerides are lowered significantly with no increase in bad cholesterol, a potential differentiating point from Pronova/Glaxo’s bloc..
Original Article: Amarin’s Vascepa May Give Lovaza A Run For Its Money
More From BioPortfolio on "Amarin’s Vascepa May Give Lovaza A Run For Its Money"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
